Danish drug-maker Novo Nordisk says its anti-obesity treatment liraglutide could become available for sale in the U.S. by the end of 2014. More
-
-
Sponsored By:
-
Sponsored By:
Pharmaceuticals
Recent Articles
2 Stocks to Buy, 2 to Sell in Big Pharma
Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries. More
New Asthma Drug Could Be Game Changer
An asthma drug developed by Sanofi and Regeneron reduced asthma attacks by 87% in a mid-stage drug trial. More
1 Stock to Buy, 1 Stock to Short: Small-Cap Pharma
The charts are showing an intermediate-term buy and a short-term shorting opportunity in these small-cap pharmaceutical stocks. More
Should I Buy Pfizer? 3 Pros, 3 Cons
Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore. More
1 Stock to Buy, 1 Stock to Short: Pharmaceuticals
We've got a micro-cap stock that looks to go even lower and a symmetrical continuation triangle that spells more upside ahead for Arena Pharmaceuticals (ARNA). More
Belviq Is Not the Next Fen-Phen … Probably
Arena Pharmaceuticals' withdrawal of its European application for Belviq has turned the stock into a three-ring circus. Don't panic -- just get the facts straight. More
